Coronavirus

How compulsory patent licensing could be used to combat covid-19 in the Americas

As the race to find coronavirus cures intensifies, we explore how legislation might be deployed in Brazil, Canada, Mexico and the US to ensure inventions are shared

How compulsory patent licensing could be used to combat covid-19 in the Americas
No evidence that patents are acting as a barrier to covid research, says Bristol Myers IP head
4 Aug 2020

No evidence that patents are acting as a barrier to covid research, says Bristol Myers IP head

Pharma giant’s deputy general counsel Henry Hadad reflects on how work has changed during the pandemic and why more still needs to be done on 101 reform

Ignore naysayers, the patent system is playing a vital role in the fight against covid-19
1 Aug 2020

Ignore naysayers, the patent system is playing a vital role in the fight against covid-19

We have learned some important IP lessons in the months since the coronavirus pandemic surged across the world; one of which is just how crucial IP itself is to finding a way out of the crisis

Latest

View all
27 Jul 2020

Indonesia makes compulsory licensing easier as high-tech waits on key patent reform

Country paves way for possible covid-19 vaccine order, but promised protections for technology firms are taking longer than anticipated Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

7 Jul 2020

How a platform technology patent list can expedite covid-19 vaccine research

More transparency around IP ownership in this vital area will help the development of treatments designed to tackle the coronavirus Read more

13 Jun 2020

It’s a great time to be involved in IP finance

Why you should expect an increase in patent-focused financing deals involving biotech and other life sciences companies Read more

News

View all
30 May 2020

Politics look set to trump patents in China’s coronavirus vaccine effort

Remarks made by Xi Jinping suggest that if a Chinese company develops a covid-19 cure, compulsory licensing’s big moment might not arrive after all Read more

26 May 2020

WHO covid-19 IP pool launches this week without strong pharma support

Open and global sharing of patents, data and know-how is seen as a step too far by many life sciences innovators Read more

25 May 2020

Japanese covid-19 patent pledge triples membership, but users must read fine print

Big-name electronics and chemical companies have continued to sign on, but several have taken the opportunity to narrow the terms of the pledge and remind potential infringers that they won’t tolerate abuse Read more

23 May 2020

The coronavirus has ended all hope of US patent eligibility reform

Opponents of stronger laws have seized the opportunity created by the pandemic to build a narrative that will make legislative changes to the 101 regime almost impossible to secure Read more

Analysis

View all
6 May 2020

How the USPTO has responded to the covid-19 pandemic

The agency's former Commissioner of Patents says it’s so far so good at the office - but explains why a backlog may build at the end of the year Read more

Insights

View all
8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more

Find an expert